Your session is about to expire
← Back to Search
Olaparib + Durvalumab for Breast Cancer (OlympiaN Trial)
OlympiaN Trial Summary
This trialexplores a new drug combination to treat breast cancer. Olaparib and durvalumab being tested to see if they can better treat and understand the disease.
OlympiaN Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowOlympiaN Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.OlympiaN Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am fully active or restricted in physically strenuous activity but can do light work.I am 18 years old or older.I haven't had major surgery in the last 2 weeks.I am able to understand and sign the consent form.I am using effective birth control methods.I haven't taken immunosuppressive drugs in the last 14 days.I am not taking any strong or moderate drugs that affect liver enzymes.My tests show a harmful change in my BRCA1 or BRCA2 gene.I had cancer before, but it was treated over 5 years ago and is not likely to come back.My organs and bone marrow are functioning well.I have not received any treatment for my current breast cancer.I have a new diagnosis of operable breast cancer that has not spread.I have a history of irregular heartbeats or uncontrolled heart rhythm problems.I am willing to have a biopsy before starting the study treatment.You have a current hepatitis B or C infection.I have or had an autoimmune or inflammatory disorder.I am HIV positive but my viral load is undetectable due to effective treatment.I have been diagnosed with MDS or AML.I have been treated with specific medications before.I am not on any cancer treatments right now.I haven't taken strong or moderate CYP3A inhibitors in the last 2 weeks.I weigh at least 30 kg.I do not have severe diseases or uncontrolled infections.I have severe, ongoing nausea or a stomach condition that affects medication absorption.
- Group 1: Cohort A
- Group 2: Cohort B
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Could I potentially be a candidate for this research study?
"Eligibility requirements for this study include a diagnosis of breast cancer and being between 18-130 years old. So far, 80 people have been enrolled in the trial."
What is the regulatory status of Cohort B?
"Cohort B's safety was given a score of 2 out of 3 because, at this stage in the clinical trial process, there is only data supporting its safety and no evidence yet of efficacy."
If I am over 35, can I participate in this clinical trial?
"Out of the 3452 clinical trials registered, this one falls in the middle with an age limit of 18-130. There are 76 trials for patients under the age of 18 and 2600 for patients over 65."
Are there still positions available for this clinical trial?
"According to the clinicaltrials.gov website, this particular trial is not looking for new patients at the moment. This study was originally posted on October 21st 2020 and was last updated on October 11th 2020. Although this research isn't recruiting right now, there are 2698 other trials that are actively searching for participants."
Share this study with friends
Copy Link
Messenger